Multiple Myeloma Presentations

Selinexor

Oral Selinexor, Pomalidomide, and Dexamethasone (XPd) at Recommended Phase 2 Dose in Relapsed Refractory Multiple Myeloma (MM)

Darrell White, QEII Health Sciences Center, Dalhousie University
8018
Hematologic Malignancies—Plasma Cell Dyscrasia
Friday, June 4, 2021; 9:00 a.m. ET

Survival Among Older Patients with Previously Treated Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd) in the BOSTON study

Thierry Facon, University Hospital
8019
Hematologic Malignancies—Plasma Cell Dyscrasia
Friday, June 4, 2021; 9:00 a.m. ET

Effects of Weekly Selinexor, Bortezomib, Dexamethasone (XVd) Versus Stand Twice Weekly bortezomib and dexamethasone (Vd) on RAS-mutated previously treated multiple myeloma (MM) Presenter: Christopher J. Walker, Karyopharm Therapeutics Inc.

Christopher J. Walker, Karyopharm Therapeutics Inc.
8027
Hematologic Malignancies—Plasma Cell Dyscrasia
Friday, June 4, 2021; 9:00 a.m. ET

Effects of Refractory Status to Lenalidomide on Safety and Efficacy of Selinexor, Bortezomib, and Dexamethasone (XVd) Versus Bortezomib and Dexamethasone (Vd) in Patients with Previously Treated Multiple Myeloma

Xavier Leleu, CHU de Poitiers, Hôpital La Mileterie
8024
Hematologic Malignancies—Plasma Cell Dyscrasia
Friday, June 4, 2021; 9:00 a.m. ET

Once Weekly Selinexor, Carfilzomib, and Dexamethasone (XKd) in Carfilzomib Nonrefractory Multiple Myeloma (MM) Patients

Cristina Gasparetto, Duke University Cancer Center
8038
Hematologic Malignancies—Plasma Cell Dyscrasia
Friday, June 4, 2021; 9:00 a.m. ET

A Randomized, Open-label, Phase 3 Study of Low-dose Selinexor and Lenalidomide (Len) Versus Len Maintenance Post Autologous Stem Cell Transplant (ASCT) for Newly Diagnosed Multiple Myeloma (NDMM): ALLG MM23, Sealand

Hang Quach, St. Vincent Hospital
TPS8055
Hematologic Malignancies—Plasma Cell Dyscrasia
Friday, June 4, 2021; 9:00 a.m. ET

Selinexor Containing Regimens in Patients with Multiple Myeloma (MM) Previously Treated with anti-CD38 Monoclonal Antibodies (CD38 mAbs)

Cristina Gasparetto, Duke University Cancer Center
e20020
Online Abstracts

U.S. Budget Impact (BI) Model for Selinexor, Bortezomib, and Dexamethasone (XVd) for the Treatment of Patients with Previously Treated Multiple Myeloma (MM)

Mike Dolph, McGill University
e18839
Online Abstracts

Solid Tumor Presentations

Selinexor

Molecular Predictors of Response to Selinexor in Advanced Unresectable De-differentiated Liposarcoma

Christopher J. Walker, Karyopharm Therapeutics Inc.
11509
Emerging Trends in Sarcoma Precision Medicine
Friday, June 4, 2021; 9:00 a.m. ET

Selinexor in Combination with Weekly Paclitaxel in Patients with Advanced or Metastatic Solid Tumors: Results of an Open Label, Single-Center, Multiarm Phase 1b Study

Shannon Westin, The University of Texas MD Anderson Cancer Center
5565
Gynecologic Cancer
Friday, June 4, 2021; 9:00 a.m. ET

A Phase 1b/2 Study of Selinexor in Combination with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST): SeliGIST/GEIS-41 Trial

Cesar Serrano, West Virginia University School of Medicine Neurology & Neurosurgery
11534
Sarcoma
Friday, June 4, 2021; 9:00 a.m. ET

Open-Label Phase 1 Study Evaluating the Tolerability and Anti-Tumor Activity of Selinexor and Pembrolizumab in Colorectal Cancer

Talia Golan, Oncology Department Center Sheba Medical Center at Tel Hashomer
e15579
Online Abstracts

SIENDO/ENGOT-EN5/GOG-3055: A Randomized Phase 3 Trial of Maintenance Selinexor Versus Placebo After Combination Platinum-based Chemotherapy in Advanced or Recurrent Endometrial Cancer

Ignace Vergote, BGOG and University Hospitals Leuven, Leuven Cancer Institute
TPS5610
Gynecologic Cancer
Friday, June 4, 2021; 9:00 a.m. ET

A Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Yazmin Odia, Miami Cancer Institute, Baptist Health South Florida (BHSF)
TPS2071
Central Nervous System Tumors
Friday, June 4, 2021; 9:00 a.m. ET

Digital Measurement of Functional Status of Patients with Glioblastoma

Yasaman Demastani, Karyopharm Therapeutics Inc.
2016
Central Nervous System Tumors
Friday, June 4, 2021; 9:00 a.m. ET

Eltanexor

Updated Overall Survival of Eltanexor for the Treatment of Patients with Hypomethylating Agent Refractory Myelodysplastic Syndrome

Sangmin Lee, Weill Cornell Medical College
e19037
Online Abstracts